Gill Capital Partners’s Evolent Health EVH Stock Holding History

Gill Capital Partners’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$211	Hold	39	–	–	﹤0.01%	672
2026 Q1	$89	Buy	+39	New	+$124	﹤0.01%	677

Other funds holding EVH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Gill Capital Partners's EVH Position: Q2 2026 in Review

Gill Capital Partners held its Evolent Health (EVH) position steady in Q2 2026 at 39 shares worth $211. The position accounts for ﹤0.01% of the portfolio, ranked #672.

Gill Capital Partners first reported a position in EVH in Q1 2026 and has held it in 2 quarters since. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

Gill Capital Partners held 39 shares of Evolent Health worth $211 as of Q2 2026.
Gill Capital Partners left its Evolent Health share count unchanged in Q2 2026.
Evolent Health made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #672 holding.
Gill Capital Partners first reported a position in Evolent Health in Q1 2026 and has held it in 2 quarters since.
199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.